Irina V. Leontyeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Irina V. Leontyeva has a total of 169 co-authors. Here are the top co-authors by number of shared publications:
- Dinara Il'GIzarovna Sadykova
Kazan State Medical University
9 shared publications - Evgeniya Sergeevna Slastnikova
Children’s Republican Clinical Hospital; Kazan State Medical University
9 shared publications - Igor A. Kovalev
A.N. Bakulev National Medical Research Center for Cardiovascular Surgery of the Russian Ministry of Health
9 shared publications - Lilia Nadipovna Galimova
Kazan State Medical University; Children’s Republican Clinical Hospital
7 shared publications - Larisa Aleksandrovna Balykova
N.P. Ogarev Mordovia State University
5 shared publications - Sergey Arturovich Termosesov
Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery of the Pirogov Russian National Research Medical University
5 shared publications
Latest Publications
- 5 October 2026
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 71 (4) , 59-67
Rhythm and conduction disorders in children with hypertrophic cardiomyopathy
Rhythm and conduction disorders remain key determinants of prognosis in hypertrophic cardiomyopathy. Objective. To assess the nature, frequency, and clinical-prognostic significance of cardiac rhythm and conduction disorders in children with hypertrophic cardiomyopathy. Materials and Methods . This retrospective-prospective study included 200 children with confirmed primary hypertrophic cardiomyopathy (median age 14.34 years; 2/3 male). Median follow-up was 5.74 years. Life-threatening arrhythmias were defined as sudden cardiac death, aborted sudden cardiac death, or appropriate implantable cardioverter-defibrillator therapy. Results. Rhythm and conduction disorders were detected in 77 % of children. Ventricular extrasystole ≥ 10/24h was observed in 25.5 %, and non-sustained ventricular tachycardia in 20.5 %. Life-threatening arrhythmias occurred in 27 children (13.5 %): sudden cardiac death (n = 6), aborted sudden cardiac death (n = 11), and appropriate implantable cardioverter-defibrillator shocks for primary prevention (n = 10). Ventricular extrasystole 10–500/24h (OR 4.93; p = 0.00002) and ventricular extrasystole ≥ 500/24h (OR 6.84; p = 0.015) were associated with non-sustained ventricular tachycardia. Extreme myocardial hypertrophy increased the odds of non-sustained ventricular tachycardia 2.3-fold (p = 0.018). Sick sinus syndrome was diagnosed in 10.5 % of children and was a strong predictor of life-threatening arrhythmias (OR 5.18; pConclusion . Hypertrophic cardiomyopathy is characterized by a high prevalence of rhythm and conduction disorders. Even moderate ventricular extrasystole is associated with non-sustained ventricular tachycardia, justifying routine Holter monitoring in all children with hypertrophic cardiomyopathy. Sick sinus syndrome is associated with a fivefold increased risk of life-threatening arrhythmias and should be incorporated into sudden cardiac death risk stratification algorithms. Such patients may warrant a lower 5-year sudden cardiac death risk threshold for dual-chamber cardioverter-defibrillator implantation.
- 5 October 2026
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 71 (4) , 59-67
Rhythm and conduction disorders in children with hypertrophic cardiomyopathy
Rhythm and conduction disorders remain key determinants of prognosis in hypertrophic cardiomyopathy. Objective. To assess the nature, frequency, and clinical-prognostic significance of cardiac rhythm and conduction disorders in children with hypertrophic cardiomyopathy. Materials and Methods . This retrospective-prospective study included 200 children with confirmed primary hypertrophic cardiomyopathy (median age 14.34 years; 2/3 male). Median follow-up was 5.74 years. Life-threatening arrhythmias were defined as sudden cardiac death, aborted sudden cardiac death, or appropriate implantable cardioverter-defibrillator therapy. Results. Rhythm and conduction disorders were detected in 77 % of children. Ventricular extrasystole ≥ 10/24h was observed in 25.5 %, and non-sustained ventricular tachycardia in 20.5 %. Life-threatening arrhythmias occurred in 27 children (13.5 %): sudden cardiac death (n = 6), aborted sudden cardiac death (n = 11), and appropriate implantable cardioverter-defibrillator shocks for primary prevention (n = 10). Ventricular extrasystole 10–500/24h (OR 4.93; p = 0.00002) and ventricular extrasystole ≥ 500/24h (OR 6.84; p = 0.015) were associated with non-sustained ventricular tachycardia. Extreme myocardial hypertrophy increased the odds of non-sustained ventricular tachycardia 2.3-fold (p = 0.018). Sick sinus syndrome was diagnosed in 10.5 % of children and was a strong predictor of life-threatening arrhythmias (OR 5.18; pConclusion . Hypertrophic cardiomyopathy is characterized by a high prevalence of rhythm and conduction disorders. Even moderate ventricular extrasystole is associated with non-sustained ventricular tachycardia, justifying routine Holter monitoring in all children with hypertrophic cardiomyopathy. Sick sinus syndrome is associated with a fivefold increased risk of life-threatening arrhythmias and should be incorporated into sudden cardiac death risk stratification algorithms. Such patients may warrant a lower 5-year sudden cardiac death risk threshold for dual-chamber cardioverter-defibrillator implantation.
- 21 July 2026
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 71 (3) , 57-68
Cross-sectional cohort multicentral study “RUSICH” Russian universal screening of total cholesterol in children of the European part of Russia
Screening for hypercholesterolemia in children is important for the early atherosclerosis prevention’s initiation. No screening for hypercholesterolemia in children in Russia has been conducted to date. Objective . To conduct universal screening for total cholesterol in a randomized sample of children aged 10 years to 10 years and 11 months across eight regions of the Russian Federation. Materials and methods . Cross-sectional, multicenter cohort study was conducted, during which 15,557 children aged 10 years to 10 years and 11 months (49.5% boys, 50.5% girls) were examined. The study protocol included obtaining informed consent, administering a questionnaire, analyzing Form F-112/U, anthropometric measurements with assessment using WHO AnthroPlus, testing for total cholesterol levels using a rapid method with the MultiCare-in device (Italy). Results . When total cholesterol levels were assessed from capillary blood, 39.1% ( n =6,165) of the children had normal levels (up to 4.4 mmol/L, inclusive), borderline values (4.5–5.1 mmol/L) were found in 28.6% ( n =4,510), and high levels ( ≥ 5.2 mmol/L) were observed in 32.4% ( n =5,112) of children. Statistically significant association was found between high total cholesterol levels and a family history of cardiovascular disease. Association between high cholesterol levels and obesity (6.0%), moderate protein-energy malnutrition (4.7%), and severe protein-energy malnutrition (1.2%) was found. High levels of physical activity were not associated with a reduction in cholesterol levels. Conclusions . Universal cholesterol screening of children has proven effective in the population of 10-year-olds in Russia for detecting hypercholesterolemia, making it an effective tool for the early identification of patients at risk for cardiovascular disease.
- 21 July 2026
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 71 (3) , 57-68
Cross-sectional cohort multicentral study “RUSICH” Russian universal screening of total cholesterol in children of the European part of Russia
Screening for hypercholesterolemia in children is important for the early atherosclerosis prevention’s initiation. No screening for hypercholesterolemia in children in Russia has been conducted to date. Objective . To conduct universal screening for total cholesterol in a randomized sample of children aged 10 years to 10 years and 11 months across eight regions of the Russian Federation. Materials and methods . Cross-sectional, multicenter cohort study was conducted, during which 15,557 children aged 10 years to 10 years and 11 months (49.5% boys, 50.5% girls) were examined. The study protocol included obtaining informed consent, administering a questionnaire, analyzing Form F-112/U, anthropometric measurements with assessment using WHO AnthroPlus, testing for total cholesterol levels using a rapid method with the MultiCare-in device (Italy). Results . When total cholesterol levels were assessed from capillary blood, 39.1% ( n =6,165) of the children had normal levels (up to 4.4 mmol/L, inclusive), borderline values (4.5–5.1 mmol/L) were found in 28.6% ( n =4,510), and high levels ( ≥ 5.2 mmol/L) were observed in 32.4% ( n =5,112) of children. Statistically significant association was found between high total cholesterol levels and a family history of cardiovascular disease. Association between high cholesterol levels and obesity (6.0%), moderate protein-energy malnutrition (4.7%), and severe protein-energy malnutrition (1.2%) was found. High levels of physical activity were not associated with a reduction in cholesterol levels. Conclusions . Universal cholesterol screening of children has proven effective in the population of 10-year-olds in Russia for detecting hypercholesterolemia, making it an effective tool for the early identification of patients at risk for cardiovascular disease.
- 25 April 2026
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 71 (2)
Early diagnosis and treatment of hypercholesterolemia in children as a key to reducing mortality from cardiovascular diseases
Coronary heart disease, which is caused by coronary atherosclerosis, is the largest contributor to cardiovascular mortality. Atherosclerosis originates in childhood. This article presents data on the prevalence and etiology of familial hypercholesterolemia, characterized by high levels of low-density lipoprotein cholesterol. This leads to the onset of atherosclerotic vascular disease in childhood and the development of myocardial infarction in the second or third decade of life. The disease is asymptomatic for a long time, especially in childhood, and therefore its detection rate is less than 1%. Diagnostic criteria and genetic aspects of the disease are outlined, and various screening options for hypercholesterolemia are discussed. A strategy for the primary prevention of cardiovascular disease is presented, and current drug therapy options are discussed. Indications for the use of statins, cholesterol absorption inhibitors, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are presented. It is demonstrated that early detection of familial hypercholesterolemia in children will facilitate the timely initiation of lipid-lowering therapy, which will halt the progression of atherosclerosis and prevent the development of coronary heart disease.
- 25 April 2026
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 71 (2)
Early diagnosis and treatment of hypercholesterolemia in children as a key to reducing mortality from cardiovascular diseases
Coronary heart disease, which is caused by coronary atherosclerosis, is the largest contributor to cardiovascular mortality. Atherosclerosis originates in childhood. This article presents data on the prevalence and etiology of familial hypercholesterolemia, characterized by high levels of low-density lipoprotein cholesterol. This leads to the onset of atherosclerotic vascular disease in childhood and the development of myocardial infarction in the second or third decade of life. The disease is asymptomatic for a long time, especially in childhood, and therefore its detection rate is less than 1%. Diagnostic criteria and genetic aspects of the disease are outlined, and various screening options for hypercholesterolemia are discussed. A strategy for the primary prevention of cardiovascular disease is presented, and current drug therapy options are discussed. Indications for the use of statins, cholesterol absorption inhibitors, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are presented. It is demonstrated that early detection of familial hypercholesterolemia in children will facilitate the timely initiation of lipid-lowering therapy, which will halt the progression of atherosclerosis and prevent the development of coronary heart disease.
- 24 April 2026
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 66 (3) , 25-35
Homozygous Familial Hypercholesterolemia in Russia: Data From the RENAISSANCE Registry
Aim To evaluate the clinical, demographic, and molecular genetic characteristics of patients with homozygous familial hypercholesterolemia (HoFH), as well as the effectiveness of lipid-lowering therapy and the incidence of cardiovascular complications, based on the RENAISSANCE registry (Registry of patiENts with FH and very high cArdIovaScular riSk pAtients with iNuffiCient rEsponse to lipid-lowering therapy). Material and methods The RENAISSANCE registry is an open-label, national observational study involving patients with FH. The diagnosis of HoFH was established according to the 2014 European Atherosclerosis Society criteria. The study accounted for atherosclerosis risk factors, physical examination findings, cardiovascular history, and current lipid-lowering therapy. Lipid profile parameters included concentrations of total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol (LDL-C), and lipoprotein(a). Most patients underwent genetic testing for hypercholesterolemia. The study's endpoint comprised fatal and non-fatal cardiovascular events. Results The study included 6 children and 13 adults (6 males) with HoFH. The mean age was 26±14 years; an average follow-up period in the registry was 5.3±2.8 years. Tendon xanthomas were observed in 68% of patients, cutaneous xanthomas in 74%, and corneal arcus in 47%. The mean age of cardiovascular disease onset was 22 ± 8 years. Ischemic heart disease was diagnosed in 63% of patients, and 47% had undergone cardiovascular interventions (arterial revascularization, aortic valve replacement). The mortality rate reached 21%. Peak LDL-C level was 17.7±4.0 mmol/L. By the final visit, LDL-C had decreased by 46% to 9.6±5.6 mmol/L, though only four patients (21%) achieved an LDL-C level ≤3 mmol/L. The median lipoprotein(a) concentration was 100 [27; 145] mg/dL, with elevated levels (≥30 mg/dL) identified in 10 patients (67%). Treatment regimens included statins (95%), ezetimibe (95%), PCSK9 inhibitors (37%), and lomitapide (21%); 53% of patients underwent lipoprotein apheresis. During the follow-up period, 14 cardiovascular events occurred across 7 patients (including one child): 4 coronary artery bypass grafts, 6 aortic valve replacements, and 4 deaths. Conclusion In the registry-based observational study of patients with HoFH, there was an increase in the use of complex combination therapies, including lipoprotein apheresis and lomitapide. However, reaching target LDL-C levels remains challenging, and the incidence of cardiovascular complications remains high.
- 24 April 2026
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 66 (3) , 25-35
Homozygous Familial Hypercholesterolemia in Russia: Data From the RENAISSANCE Registry
Aim To evaluate the clinical, demographic, and molecular genetic characteristics of patients with homozygous familial hypercholesterolemia (HoFH), as well as the effectiveness of lipid-lowering therapy and the incidence of cardiovascular complications, based on the RENAISSANCE registry (Registry of patiENts with FH and very high cArdIovaScular riSk pAtients with iNuffiCient rEsponse to lipid-lowering therapy). Material and methods The RENAISSANCE registry is an open-label, national observational study involving patients with FH. The diagnosis of HoFH was established according to the 2014 European Atherosclerosis Society criteria. The study accounted for atherosclerosis risk factors, physical examination findings, cardiovascular history, and current lipid-lowering therapy. Lipid profile parameters included concentrations of total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol (LDL-C), and lipoprotein(a). Most patients underwent genetic testing for hypercholesterolemia. The study's endpoint comprised fatal and non-fatal cardiovascular events. Results The study included 6 children and 13 adults (6 males) with HoFH. The mean age was 26±14 years; an average follow-up period in the registry was 5.3±2.8 years. Tendon xanthomas were observed in 68% of patients, cutaneous xanthomas in 74%, and corneal arcus in 47%. The mean age of cardiovascular disease onset was 22 ± 8 years. Ischemic heart disease was diagnosed in 63% of patients, and 47% had undergone cardiovascular interventions (arterial revascularization, aortic valve replacement). The mortality rate reached 21%. Peak LDL-C level was 17.7±4.0 mmol/L. By the final visit, LDL-C had decreased by 46% to 9.6±5.6 mmol/L, though only four patients (21%) achieved an LDL-C level ≤3 mmol/L. The median lipoprotein(a) concentration was 100 [27; 145] mg/dL, with elevated levels (≥30 mg/dL) identified in 10 patients (67%). Treatment regimens included statins (95%), ezetimibe (95%), PCSK9 inhibitors (37%), and lomitapide (21%); 53% of patients underwent lipoprotein apheresis. During the follow-up period, 14 cardiovascular events occurred across 7 patients (including one child): 4 coronary artery bypass grafts, 6 aortic valve replacements, and 4 deaths. Conclusion In the registry-based observational study of patients with HoFH, there was an increase in the use of complex combination therapies, including lipoprotein apheresis and lomitapide. However, reaching target LDL-C levels remains challenging, and the incidence of cardiovascular complications remains high.
- 20 April 2026
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 71 (1)
Management of the dyslipidemia in children and adolescents
Cardiovascular diseases are one of the most common causes of disability and mortality in the young working age population worldwide. Atherosclerosis is a key pathological process that leads to early cardiovascular catastrophes, including heart attacks, strokes and ischemic heart disease. Timely diagnosis of dyslipidemia can ensure the initiation of effective treatment and prevention. Hereditary forms of lipid metabolism disorders are particularly dangerous and require close attention, starting from childhood. One of the effective methods for diagnosing dyslipidemia is screening of blood cholesterol levels. The world practice includes several types of screening, but the most commonly used are selective and universal. In the Russian Federation, until now, measurement of cholesterol levels has not been included in any examination of a child as part of dispensary monitoring. The new resolution pays special attention to children from risk groups and the measurement of total cholesterol from capillary blood at the ages of 6 and 10 years.
- 20 April 2026
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 71 (1)
Management of the dyslipidemia in children and adolescents
Cardiovascular diseases are one of the most common causes of disability and mortality in the young working age population worldwide. Atherosclerosis is a key pathological process that leads to early cardiovascular catastrophes, including heart attacks, strokes and ischemic heart disease. Timely diagnosis of dyslipidemia can ensure the initiation of effective treatment and prevention. Hereditary forms of lipid metabolism disorders are particularly dangerous and require close attention, starting from childhood. One of the effective methods for diagnosing dyslipidemia is screening of blood cholesterol levels. The world practice includes several types of screening, but the most commonly used are selective and universal. In the Russian Federation, until now, measurement of cholesterol levels has not been included in any examination of a child as part of dispensary monitoring. The new resolution pays special attention to children from risk groups and the measurement of total cholesterol from capillary blood at the ages of 6 and 10 years.
- Open Access
- 20 December 2025
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 22 (4) , 5-58
Arterial hypertension in children. Clinical guidelines 2025
Clinical guideline developers: Association of Pediatric Cardiologists of Russia, Russian Medical Society for Arterial Hypertension Coding according to the International Statistical Classification of Diseases and Related Health Problems: ICD-10: I10/ I11/ I12/ I13/ I15/ P29.2 Age group: Children Year of approval: 2025
- 20 December 2025
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 22 (4) , 5-58
Open AccessArterial hypertension in children. Clinical guidelines 2025
Clinical guideline developers: Association of Pediatric Cardiologists of Russia, Russian Medical Society for Arterial Hypertension Coding according to the International Statistical Classification of Diseases and Related Health Problems: ICD-10: I10/ I11/ I12/ I13/ I15/ P29.2 Age group: Children Year of approval: 2025
- 14 November 2025
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 70 (5) , 157-167
Organization of dispensary and dynamic observation of children with heterozygous familial hypercholesterolemia: the experience of the Republic of Tatarstan
Familial hypercholesterolemia is the most common monogenic hereditary disease in which abnormally high cholesterol levels in the blood are observed since childhood. There is currently no unified approach to monitoring and stratifying cardiovascular risk for children with familial hypercholesterolemia in Russia. Aim of the study: to develop a monitoring program for children with heterozygous familial hypercholesterolemia based on a 3-year prospective observation. Materials and methods. From 2017 to 2024, a comparative prospective longitudinal cohort study was conducted at the Children’s Lipidology Center of the Republican Children’s Clinical Hospital of the Ministry of Health of the Republic of Tatarstan (Kazan). The study involved 243 children aged 5 to 17 years: 122 children diagnosed with «familial hypercholesterolemia, heterozygous form» and 121 healthy children. The children were divided into 3 age subgroups: 5–7 years, 8–12 years, 13–17 years. Special examination methods included: study of endothelin-1 level, total concentration of stable nitric oxide metabolites, apolipoprotein A1, apolipoprotein B, lipoprotein (a), high-sensitivity C-reactive protein, determination of average pulse wave velocity in the aorta, assessment of the intima-media complex of the common carotid artery. Results. Concentrations of apolipoprotein A1 and apolipoprotein B, lipoprotein (a) and high-sensitivity C-reactive protein were significantly higher in the main group and did not change with the age of the patients. The values of the intima-media thickness of the common carotid artery and pulse wave velocity, endothelin-1 level depended on the age of children with familial hypercholesterolemia. The obtained results determined the existence of regular differences in the strategy of management of patients with familial hypercholesterolemia in childhood and allowed to scientifically substantiate the program of observation of patients with heterozygous familial hypercholesterolemia in childhood. Conclusion. The proposed algorithm will allow to register early signs of vascular remodeling and to draw up a plan of personalized observation of a child with familial hypercholesterolemia.
- 14 November 2025
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 70 (5) , 157-167
Organization of dispensary and dynamic observation of children with heterozygous familial hypercholesterolemia: the experience of the Republic of Tatarstan
Familial hypercholesterolemia is the most common monogenic hereditary disease in which abnormally high cholesterol levels in the blood are observed since childhood. There is currently no unified approach to monitoring and stratifying cardiovascular risk for children with familial hypercholesterolemia in Russia. Aim of the study: to develop a monitoring program for children with heterozygous familial hypercholesterolemia based on a 3-year prospective observation. Materials and methods. From 2017 to 2024, a comparative prospective longitudinal cohort study was conducted at the Children’s Lipidology Center of the Republican Children’s Clinical Hospital of the Ministry of Health of the Republic of Tatarstan (Kazan). The study involved 243 children aged 5 to 17 years: 122 children diagnosed with «familial hypercholesterolemia, heterozygous form» and 121 healthy children. The children were divided into 3 age subgroups: 5–7 years, 8–12 years, 13–17 years. Special examination methods included: study of endothelin-1 level, total concentration of stable nitric oxide metabolites, apolipoprotein A1, apolipoprotein B, lipoprotein (a), high-sensitivity C-reactive protein, determination of average pulse wave velocity in the aorta, assessment of the intima-media complex of the common carotid artery. Results. Concentrations of apolipoprotein A1 and apolipoprotein B, lipoprotein (a) and high-sensitivity C-reactive protein were significantly higher in the main group and did not change with the age of the patients. The values of the intima-media thickness of the common carotid artery and pulse wave velocity, endothelin-1 level depended on the age of children with familial hypercholesterolemia. The obtained results determined the existence of regular differences in the strategy of management of patients with familial hypercholesterolemia in childhood and allowed to scientifically substantiate the program of observation of patients with heterozygous familial hypercholesterolemia in childhood. Conclusion. The proposed algorithm will allow to register early signs of vascular remodeling and to draw up a plan of personalized observation of a child with familial hypercholesterolemia.
- Open Access
- 11 July 2025
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 24 (3) , 193-202
“Muscle Bridge” as a Possible Risk Factor for Sudden Cardiac Death in a Child with Hypertrophic Cardiomyopathy: Case Study
Background. Hypertrophic cardiomyopathy (HCM) is one of the most common causes of sudden cardiac death (SCD) in young adults under the age of 35. SCD may be the first and only clinical manifestation of the disease in children. Case presentation. Female patient with HCM and low risk of cardiac events suffered the first episode of SCD associated with physical activity at the age of 12 years 4 months. Acute myocardial ischemia was suspected due to abnormal coronary arteries, “muscle bridge”, that was the trigger of malignant ventricular arrhythmias leading to cardiac arrest. Implantable cardioverter defibrillator (ICD) was installed for secondary SCD prevention. However, the disease has progressed, and the child suffered two more episodes due to ventricular fibrillation, managed by ICD and resuscitation measures. Drug therapy and ICD regimens were adjusted. Myocardial revascularization was not performed due to high surgical risk. Conclusion. Difficulties in management of patient with HCM complicated with acute myocardial ischemia due to congenital coronary arteries anomaly are presented. Myocardial ischemia is not considered as “large” risk factor for SCD in children (according to traditional evaluation). However, it can be a trigger for life-threatening ventricular arrhythmias and negatively affect HCM prognosis as it has been shown in our observation.
- 11 July 2025
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 24 (3) , 193-202
Open Access“Muscle Bridge” as a Possible Risk Factor for Sudden Cardiac Death in a Child with Hypertrophic Cardiomyopathy: Case Study
Background. Hypertrophic cardiomyopathy (HCM) is one of the most common causes of sudden cardiac death (SCD) in young adults under the age of 35. SCD may be the first and only clinical manifestation of the disease in children. Case presentation. Female patient with HCM and low risk of cardiac events suffered the first episode of SCD associated with physical activity at the age of 12 years 4 months. Acute myocardial ischemia was suspected due to abnormal coronary arteries, “muscle bridge”, that was the trigger of malignant ventricular arrhythmias leading to cardiac arrest. Implantable cardioverter defibrillator (ICD) was installed for secondary SCD prevention. However, the disease has progressed, and the child suffered two more episodes due to ventricular fibrillation, managed by ICD and resuscitation measures. Drug therapy and ICD regimens were adjusted. Myocardial revascularization was not performed due to high surgical risk. Conclusion. Difficulties in management of patient with HCM complicated with acute myocardial ischemia due to congenital coronary arteries anomaly are presented. Myocardial ischemia is not considered as “large” risk factor for SCD in children (according to traditional evaluation). However, it can be a trigger for life-threatening ventricular arrhythmias and negatively affect HCM prognosis as it has been shown in our observation.
- Open Access
- 27 June 2025
- Published by National Medical Research Center for Childrens Health in Russian Pediatric Journal
- Vol. 28 (3) , 223-230
Chronic heart failure in children: etiology, pathogenesis, clinical picture and diagnosis
Introduction. Chronic heart failure (CHF) is a threatening complication of cardiovascular diseases or damage in other pathological processes. CHF is characterized by a significant risk of disability and mortality in childhood. The progression of CHF of any etiology is based on the process of cardiovascular remodeling associated with the activation of neurohormonal systems, sympathicoadrenal and renin-angiotensin-aldosterone. Aim of the review: to highlight the issues of the modern view of the etiology, pathogenesis, diagnosis and clinical features in CHF children to increase the knowledge in practitioners for better management of patients. A modern pharmacological treatment method that affects the prognosis and prevents the progression of myocardial damage is based on modulation of the activity of sympathicoadrenal and renin-angiotensin-aldosterone systems at the circulating, tissue, and cellular levels. When determining the treatment of children, the etiology of CHF should be established, concomitant diseases should be identified, the variant and severity of myocardial dysfunction should be determined, and the severity of clinical manifestations should be assessed.
- 27 June 2025
- Published by National Medical Research Center for Childrens Health in Russian Pediatric Journal
- Vol. 28 (3) , 223-230
Open AccessChronic heart failure in children: etiology, pathogenesis, clinical picture and diagnosis
Introduction. Chronic heart failure (CHF) is a threatening complication of cardiovascular diseases or damage in other pathological processes. CHF is characterized by a significant risk of disability and mortality in childhood. The progression of CHF of any etiology is based on the process of cardiovascular remodeling associated with the activation of neurohormonal systems, sympathicoadrenal and renin-angiotensin-aldosterone. Aim of the review: to highlight the issues of the modern view of the etiology, pathogenesis, diagnosis and clinical features in CHF children to increase the knowledge in practitioners for better management of patients. A modern pharmacological treatment method that affects the prognosis and prevents the progression of myocardial damage is based on modulation of the activity of sympathicoadrenal and renin-angiotensin-aldosterone systems at the circulating, tissue, and cellular levels. When determining the treatment of children, the etiology of CHF should be established, concomitant diseases should be identified, the variant and severity of myocardial dysfunction should be determined, and the severity of clinical manifestations should be assessed.
- 6 March 2025
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 70 (1) , 32-41
Primary prevention of sudden cardiac death in children with hypertrophic cardiomyopathy: experience with implantable cardioverter-defibrillators
Hypertrophic cardiomyopathy is the most common cause of sudden cardiac death in both adults and children. A crucial issue is identifying children with hypertrophic cardiomyopathy (HCM) who are at high risk of sudden cardiac death and require an implantable cardioverter-defibrillator for primary prevention of sudden cardiac death.Objective. To evaluate the effectiveness of implantable cardioverter defibrillators (ICDs) as the primary prevention of sudden cardiac death in children with hypertrophic cardiomyopathy.Material and methods. Data were collected from a single pediatric center (2009–2024), including 200 children and adolescents with hypertrophic cardiomyopathy, 77 patients underwent implantation of a cardioverter defibrillator for the primary prevention of sudden cardiac death.Results. Appropriate shocks on ventricular tachycardia and ventricular fibrillation occurred in 8 out of 77 patients (10.4%) within 1.25 years (IQR 0.6–3). The median time from implantation to the first discharge was 2 years (IQR 1.2–2.3). The annual frequency of appropriate ICD shocks was 3.5% per year. A direct correlation of the responses on the number of risk factors for sudden cardiac death was obtained. In patients with two or more risk factors, the likelihood of motivated response was 12 times higher than in those with fewer risk factors (OR/OR 12.12; CI 95% 1.47–99.65). The values of 5-year risk of sudden cardiac death >16% (HCM Risk-Kids) and >11.9% (HCM Risk-SCD) had the best prognostic value (AUC 0.738; pConclusion. The high prognostic significance of the factorial approach to the stratification of the risk of SCD in children with HCM has been established. It is necessary to further improve the cut-off points for determining indications for implantation of cardioverter defibrillators in children based on 5-year models of sudden cardiac death in pediatric patients.
- 6 March 2025
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 70 (1) , 32-41
Primary prevention of sudden cardiac death in children with hypertrophic cardiomyopathy: experience with implantable cardioverter-defibrillators
Hypertrophic cardiomyopathy is the most common cause of sudden cardiac death in both adults and children. A crucial issue is identifying children with hypertrophic cardiomyopathy (HCM) who are at high risk of sudden cardiac death and require an implantable cardioverter-defibrillator for primary prevention of sudden cardiac death.Objective. To evaluate the effectiveness of implantable cardioverter defibrillators (ICDs) as the primary prevention of sudden cardiac death in children with hypertrophic cardiomyopathy.Material and methods. Data were collected from a single pediatric center (2009–2024), including 200 children and adolescents with hypertrophic cardiomyopathy, 77 patients underwent implantation of a cardioverter defibrillator for the primary prevention of sudden cardiac death.Results. Appropriate shocks on ventricular tachycardia and ventricular fibrillation occurred in 8 out of 77 patients (10.4%) within 1.25 years (IQR 0.6–3). The median time from implantation to the first discharge was 2 years (IQR 1.2–2.3). The annual frequency of appropriate ICD shocks was 3.5% per year. A direct correlation of the responses on the number of risk factors for sudden cardiac death was obtained. In patients with two or more risk factors, the likelihood of motivated response was 12 times higher than in those with fewer risk factors (OR/OR 12.12; CI 95% 1.47–99.65). The values of 5-year risk of sudden cardiac death >16% (HCM Risk-Kids) and >11.9% (HCM Risk-SCD) had the best prognostic value (AUC 0.738; pConclusion. The high prognostic significance of the factorial approach to the stratification of the risk of SCD in children with HCM has been established. It is necessary to further improve the cut-off points for determining indications for implantation of cardioverter defibrillators in children based on 5-year models of sudden cardiac death in pediatric patients.